CRBP
Corbus Pharmaceuticals Holdings, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-32/100
Last price
5.78
▼ 0.07 (1.20%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
5.85
Day high
6.00
Day low
5.65
Volume
707.45K
Market cap
$111.79M
P/E (TTM)
—
52W range
5.65 – 20.56
Trailing performance
Returnvs SPY
1W
-12.82%
-14.8%
1M
-47.83%
-49.0%
3M
-39.48%
-44.0%
6M
-40.47%
-58.7%
YTD
-28.99%
-43.2%
1Y
-61.02%
-77.4%
3Y
-14.24%
-96.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CRBP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+119.00K
Net buying
Buy transactions
10
159.23K shares
Sell transactions
6
40.24K shares
Net transactions
+16
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
239.06K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 14, 26 | BEN YONG Director |
SELL | 2.00K | $15.68K | Direct |
| Aug 14, 26 | NICACIO LEONARDO VIANA M.D. Officer |
STOCK | 58.33K | $0 | Direct |
| Aug 11, 26 | SAXENA NISHANT C Officer |
BUY | 2.60K | $25.04K | Direct |
| Aug 7, 26 | MORAN SEAN F Chief Financial Officer |
SELL | 12.00K | $120.97K | Direct |
| Aug 7, 26 | COHEN YUVAL Chief Executive Officer |
SELL | 17.00K | $171.40K | Direct |
| Jun 10, 26 | KUNG WINSTON Director |
SELL | 2.03K | $16.03K | Direct |
| Jun 10, 26 | JENKINS JOHN KENNETH M.D. Director |
SELL | 4.80K | $37.99K | Direct |
| Jun 10, 26 | ALTMEYER ANNE Director |
SELL | 2.41K | $19.09K | Direct |
| Jun 3, 26 | SAXENA NISHANT C Officer |
BUY | 13.50K | $101.22K | Direct |
| May 21, 26 | SAXENA NISHANT C Officer |
STOCK | 58.30K | $0 | Direct |
| May 19, 26 | KUNG WINSTON Director |
STOCK | 3.80K | $0 | Direct |
| May 19, 26 | JENKINS JOHN KENNETH M.D. Director |
STOCK | 3.80K | $0 | Direct |
| May 19, 26 | JACQUES RACHELLE SUZANNE Director |
STOCK | 3.80K | $0 | Direct |
| May 19, 26 | ALTMEYER ANNE Director |
STOCK | 3.80K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
COHEN YUVAL |
Chief Executive Officer | 157.32K | Sale |
CORMORANT ASSET MANAGEMENT ,L.P |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
HODGSON IAN |
Chief Operating Officer | 51.08K | Sale |
HOLMER ALAN F |
Director | 10.63K | Stock Award(Grant) |
JACQUES RACHELLE SUZANNE |
Director | 11.38K | Stock Award(Grant) |
KUNG WINSTON |
Director | 12.14K | Sale |
MORAN SEAN F |
Chief Financial Officer | 84.69K | Sale |
NICACIO LEONARDO VIANA M.D. |
Officer | 58.33K | Stock Award(Grant) |
SAXENA NISHANT C |
Officer | 77.90K | Purchase |
SMETHURST DOMINIC |
Officer | 89.79K | Sale |
Fundamentals
Market cap$111.79M
Enterprise value$-1.88M
Revenue (TTM)—
Gross profit$-90.26M
EBITDA$-106.68M
Net income$-101.90M
EPS (TTM)$-6.11
Free cash flow$-49.62M
Total cash$117.94M
Total debt$4.26M
Book value / share$5.48
Shares outstanding19.34M
Float13.25M
Short % of float16.33%
Dividend yield0.00%
Beta (5Y)2.63
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.05
PEG ratio—
Price / sales—
Price / book1.06
EV / revenue—
EV / EBITDA0.02
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-95.58%
Return on assets-53.00%
Debt / equity4.17
Current ratio5.71
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $70.09M | $32.22M | $31.17M | $16.14M | +117.5% |
| Selling, general & admin | $15.21M | $16.50M | $13.91M | $18.70M | -7.8% |
| Total operating expense | $85.31M | $48.72M | $45.08M | $34.84M | +75.1% |
| Operating income | -$85.31M | -$48.72M | -$45.08M | -$34.84M | -75.1% |
| Net interest income | $5.53M | $4.44M | -$2.22M | -$2.13M | +24.6% |
| Pre-tax income | -$78.54M | -$40.21M | -$44.60M | -$42.35M | -95.3% |
| Net income | -$78.54M | -$40.21M | -$44.60M | -$42.35M | -95.3% |
| Net income to common | -$78.54M | -$40.21M | -$44.60M | -$42.35M | -95.3% |
| Basic EPS | -5.90 | -3.68 | -10.31 | -10.15 | -60.3% |
| Diluted EPS | -5.90 | -3.68 | -10.31 | -10.15 | -60.3% |
| EBIT | -$78.54M | -$38.34M | -$40.75M | -$34.84M | -104.9% |
| EBITDA | -$78.30M | -$37.75M | -$40.10M | -$34.07M | -107.4% |
| Basic shares | 13.32M | 10.92M | 4.33M | 4.17M | +22.0% |
| Diluted shares | 13.32M | 10.92M | 4.33M | 4.17M | +22.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.49M | $17.20M | $13.72M | $17.00M | — | +65.7% |
| Cash & short-term investments | $163.27M | $149.06M | $20.91M | $59.20M | — | +9.5% |
| Total current assets | $166.95M | $152.98M | $23.55M | $60.18M | — | +9.1% |
| Property, plant & equipment | $1.24M | $2.52M | $4.04M | $5.50M | — | -50.7% |
| Total assets | $168.19M | $155.88M | $28.27M | $66.31M | — | +7.9% |
| Total current liabilities | $20.69M | $11.82M | $31.89M | $12.64M | — | +75.1% |
| Current debt | — | — | $16.21M | $3.15M | $3.86M | — |
| Long-term debt | — | — | — | $15.98M | $15.64M | — |
| Total debt | $1.63M | $3.24M | $20.89M | $25.09M | — | -49.6% |
| Total liabilities | $20.69M | $13.45M | $35.18M | $33.32M | — | +53.8% |
| Retained earnings | -$555.43M | -$476.89M | -$436.68M | -$392.08M | — | -16.5% |
| Shareholder equity | $147.50M | $142.43M | -$6.91M | $32.99M | — | +3.6% |
| Working capital | $146.26M | $141.16M | -$8.35M | $47.54M | — | +3.6% |
| Net tangible assets | $147.50M | $142.43M | -$6.91M | $32.99M | — | +3.6% |
| Shares issued | 17.61M | 12.18M | 4.42M | 4.17M | — | +44.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$78.54M | -$40.21M | -$44.60M | -$42.35M | — | -95.3% |
| Depreciation & amortisation | $233.00K | $588.00K | $641.00K | $763.00K | — | -60.4% |
| Stock-based compensation | $6.29M | $6.14M | $3.47M | $5.72M | — | +2.3% |
| Change in working capital | $9.12M | -$5.58M | $4.09M | -$3.30M | — | +263.6% |
| Operating cash flow | -$64.49M | -$41.79M | -$36.10M | -$37.54M | — | -54.3% |
| Capital expenditure | -$7.00K | — | — | -$13.45K | -$54.17K | — |
| Investing cash flow | -$1.64M | -$121.31M | $35.64M | $30.07M | — | +98.6% |
| Financing cash flow | $77.43M | $166.58M | -$2.82M | -$533.62K | — | -53.5% |
| Free cash flow | -$64.50M | -$41.79M | -$36.10M | -$37.56M | — | -54.3% |
| End cash position | $29.16M | $17.87M | $14.39M | $17.67M | — | +63.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $31.18M | $19.82M | $18.41M | $20.86M | $15.19M | +57.3% |
| Selling, general & admin | $5.01M | $4.49M | $3.56M | $3.56M | $3.96M | +11.8% |
| Total operating expense | $36.19M | $24.30M | $21.97M | $24.42M | $19.15M | +48.9% |
| Operating income | -$36.19M | -$24.30M | -$21.97M | -$24.42M | -$19.15M | -48.9% |
| Net interest income | $1.16M | $1.40M | $1.41M | $1.13M | $1.31M | -17.0% |
| Pre-tax income | -$35.04M | -$22.97M | -$20.55M | -$23.34M | -$17.66M | -52.5% |
| Net income | -$35.04M | -$22.97M | -$20.55M | -$23.34M | -$17.66M | -52.5% |
| Net income to common | -$35.04M | -$22.97M | -$20.55M | -$23.34M | -$17.66M | -52.5% |
| Basic EPS | -1.81 | -1.23 | -1.25 | -1.90 | -1.44 | -47.2% |
| Diluted EPS | -1.81 | -1.23 | -1.25 | -1.90 | -1.44 | -47.2% |
| EBIT | -$36.19M | -$24.30M | -$20.55M | -$23.34M | -$19.15M | -48.9% |
| EBITDA | -$36.14M | -$24.25M | -$20.51M | -$23.29M | -$19.10M | -49.0% |
| Basic shares | 19.41M | 18.71M | 16.48M | 12.31M | 12.24M | +3.7% |
| Diluted shares | 19.41M | 18.71M | 16.48M | 12.31M | 12.24M | +3.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $23.37M | $25.66M | $28.49M | $26.98M | $20.04M | -8.9% |
| Cash & short-term investments | $117.94M | $138.22M | $163.27M | $103.98M | $116.59M | -14.7% |
| Total current assets | $122.75M | $143.57M | $166.95M | $107.57M | $122.83M | -14.5% |
| Property, plant & equipment | $3.85M | $914.00K | $1.24M | $1.56M | $1.88M | +321.2% |
| Total assets | $126.99M | $144.48M | $168.19M | $109.51M | $125.08M | -12.1% |
| Total current liabilities | $21.48M | $18.14M | $20.69M | $17.06M | $13.33M | +18.4% |
| Total debt | $4.26M | $1.21M | $1.63M | $2.05M | $2.46M | +253.9% |
| Total liabilities | $24.75M | $18.14M | $20.69M | $17.37M | $14.09M | +36.4% |
| Retained earnings | -$613.44M | -$578.40M | -$555.43M | -$534.88M | -$511.53M | -6.1% |
| Shareholder equity | $102.24M | $126.34M | $147.50M | $92.15M | $110.99M | -19.1% |
| Working capital | $101.27M | $125.43M | $146.26M | $90.51M | $109.49M | -19.3% |
| Net tangible assets | $102.24M | $126.34M | $147.50M | $92.15M | $110.99M | -19.1% |
| Shares issued | 17.74M | 17.74M | 17.61M | 12.53M | 12.25M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$35.04M | -$22.97M | -$20.55M | -$23.34M | -$17.66M | — | -52.5% |
| Depreciation & amortisation | $51.00K | $49.00K | $49.00K | $50.00K | $53.00K | — | +4.1% |
| Stock-based compensation | $1.81M | $1.92M | $1.43M | $1.58M | $1.56M | — | -5.7% |
| Change in working capital | $3.77M | -$4.30M | $3.83M | $6.16M | $122.00K | — | +187.6% |
| Operating cash flow | -$29.63M | -$25.57M | -$15.92M | -$15.55M | -$16.60M | — | -15.9% |
| Capital expenditure | -$6.00K | -$6.00K | — | — | — | — | 0.0% |
| Investing cash flow | $18.26M | $22.45M | -$57.15M | $19.64M | $17.74M | — | -18.7% |
| Financing cash flow | — | — | $74.58M | $2.85M | $0 | $0 | — |
| Free cash flow | -$29.63M | -$25.58M | -$15.93M | -$15.55M | -$16.60M | — | -15.9% |
| End cash position | $23.75M | $26.05M | $29.16M | $27.65M | $20.71M | — | -8.8% |
Options analytics
Put / call volume
0.33
Call-heavy session
Put / call open interest
6.84
Positioning, not flow
Max pain
7.50
+29.8% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-25.0%
Calls bid over puts
Call volume
36
Contracts, this expiry
Put volume
12
Contracts, this expiry
Heaviest call OI
7.50
171 contracts
Heaviest put OI
5.00
1.05K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.24 | -1.81 | -46.3% |
| Mar 2026 | -1.22 | -1.23 | -0.8% |
| Dec 2025 | -1.58 | -1.25 | +20.7% |
| Sep 2025 | -1.71 | -1.90 | -11.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.21 | 10 | $1.11M | 0.0% |
| Next quarter | -1.32 | 10 | $0 | 0.0% |
| Current year | -5.43 | 10 | $1.11M | 0.0% |
| Next year | -5.51 | 9 | $2.40M | +116.0% |
Analyst targets & ownership
Mean target$34.03
High target$48.00
Low target$17.25
Implied upside488.67%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy0 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders1.24%
Held by institutions84.15%
Institutions holding141
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
6.68
-13.47% from price
SMA 20
7.23
-20.02% from price
SMA 50
9.00
-35.81% from price
SMA 100
8.91
-35.12% from price
SMA 200
8.95
-35.40% from price
EMA 12
6.75
-14.39% from price
EMA 26
7.68
-24.72% from price
EMA 50
8.39
-31.09% from price
RSI (14)
23.9
Oversold
MACD (12,26,9)
-0.93
Hist -0.12
ATR (14)
0.44
7.53% of price
Realised vol 30D
80.8%
Annualised
Bollinger upper
8.83
20, 2σ
Bollinger lower
5.62
20, 2σ
50 / 200 cross
Golden
9.00 vs 8.95
Trend bias
Below 200
-35.40%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.11
More volatile than market
Correlation to SPY
0.18
Largely independent
Realised vol 30D
80.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-70.1%
Peak to trough
Max drawdown 5Y
-93.6%
Peak to trough
ATR 14
0.44
7.53% of price
Beta (reported)
2.63
5Y monthly, from filing
Short interest
Shares short
2.76M
Prior 2.15M
Change vs prior
+28.5%
Shorts adding
% of float
16.33%
Elevated
% of shares out
14.27%
Against total outstanding
Days to cover
2.2
Liquid
Float
13.25M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Aug 7, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 23, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jun 17, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 27, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 26, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 22, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| May 13, 26 | Jefferies | MAINTAINED | Buy | Buy |
| May 13, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 13, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Apr 29, 26 | Guggenheim | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:30
Split dateFeb 14, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-14
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-06
Offering Registrations
S-8 · 2026-06-17
Offering Registrations
S-8 · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-26
Corporate Changes & Voting Matters
8-K · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-14
Headlines
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
GlobeNewswire · 8d ago
Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?
Zacks · 20d ago
Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study
MarketBeat · 22d ago
Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data
InvestorsHub · 23d ago
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
GlobeNewswire · 23d ago
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
GlobeNewswire · 26d ago
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 51d ago
Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating
MT Newswires · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.